<SEC-DOCUMENT>0001790670-19-000002.txt : 20191107
<SEC-HEADER>0001790670-19-000002.hdr.sgml : 20191107
<ACCEPTANCE-DATETIME>20191107203145
ACCESSION NUMBER:		0001790670-19-000002
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20191107
FILED AS OF DATE:		20191107
DATE AS OF CHANGE:		20191107

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Ellis Ronald J. Jr.
		CENTRAL INDEX KEY:			0001790670

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39130
		FILM NUMBER:		191201864

	MAIL ADDRESS:	
		STREET 1:		C/O TELA BIO, INC.
		STREET 2:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pacira BioSciences, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39130
		FILM NUMBER:		191201865

	BUSINESS ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054
		BUSINESS PHONE:		973-254-3560

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER NAME:	
		FORMER CONFORMED NAME:	Pacira Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20101029

	FORMER NAME:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER NAME:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TELA Bio, Inc.
		CENTRAL INDEX KEY:			0001561921
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				455320061
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-320-2930

	MAIL ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2019-11-07</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001561921</issuerCik>
        <issuerName>TELA Bio, Inc.</issuerName>
        <issuerTradingSymbol>TELA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001790670</rptOwnerCik>
            <rptOwnerName>Ellis Ronald J. Jr.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PACIRA PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>5 SYLVAN WAY, SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>PARSIPPANY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001396814</rptOwnerCik>
            <rptOwnerName>Pacira BioSciences, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>5 SYLVAN WAY, SUITE 300</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PARSIPPANY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07054</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series B Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>580357</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Pacira Pharmaceuticals, Inc.</value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.00</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2029-11-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>5331</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Shares of Series B Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the &quot;Certificate of Incorporation&quot;)). The shares of Series B Preferred Stock will automatically convert into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment in cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.</footnote>
        <footnote id="F2">Shares of Series B Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate.</footnote>
        <footnote id="F3">The option vests in 36 equal monthly installments on each monthly anniversary of November 7, 2019, subject to the Reporting Person's continuous service with the Issuer.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Nora Brennan as attorney-in-fact for Ronald J. Ellis, Jr.</signatureName>
        <signatureDate>2019-11-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poaellis.htm
<TEXT>
<HTML><BODY><PRE>                                POWER OF ATTORNEY



 Know all by these presents, that the undersigned hereby constitutes

and appoints Nora Brennan and Frank Conway with full power to act singly,

as the undersigned's true and lawful attorney-in-fact, with full power of

substitution, to:



 (1) execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer and/or director and/or beneficial owner of Tela Bio,

Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of

the Securities Exchange Act of 1934, as amended, and the rules thereunder;



 (2) do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute any

such Form 3, 4, or 5, complete and execute any amendment or amendments thereto,

and timely file such form with the United States Securities and Exchange

Commission and any stock exchange or similar authority; and



 (3) take any other action of any type whatsoever in connection with

the foregoing which, in the opinion of such attorney-in-fact, may be of benefit

to, in the best interest of, or legally required by, the undersigned, it being

understood that the documents executed by such attorney-in-fact on behalf of

the undersigned pursuant to this Power of Attorney shall be in such form and

shall contain such terms and conditions as such attorney-in-fact may approve

in such attorney-in-fact's discretion.



 The undersigned hereby grants to the attorneys-in-fact full power and

authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this power of attorney and the rights and powers herein

granted.



 This power of attorney shall remain in full force and effect until

revoked by the undersigned in a signed writing delivered to the attorney-in-fact.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of this 26th day of September, 2019.







     /s/Ronald J. Ellis, Jr.

     Name: Ronald J. Ellis, Jr.

     Title: Director



</PRE></BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
